查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球骨髓增生異常症候群（MDS）治療市場 - 2023-2030年
市場調查報告書
商品編碼
1290358

全球骨髓增生異常症候群（MDS）治療市場 - 2023-2030年

Global Myelodysplastic Syndrome (MDS) Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球骨髓增生異常綜合症（MDS）治療市場在2022年達到30.655億美元，預計到2030年將見證有利可圖的成長，達到60.595億美元。全球骨髓增生異常綜合症治療市場在預測期內（2023-2030年）預計將呈現9.1%的複合成長率。

幹細胞移植是推動全球骨髓增生異常綜合症治療市場的主要趨勢之一。骨髓增生異常症候群患者的治愈性治療方案- 造血幹細胞移植（HSCT），也一直是研發工作的主題。通過研究，人們對影響移植成功的因素，如供體選擇、調理方案和移植物抗宿主疾病預防技術，有了更好的了解。

此外，骨髓增生異常綜合症的免疫療法的發展是另一個研究和發展領域。這些治療方法利用身體的免疫系統來尋找和摧毀惡性或病態細胞。例如，免疫檢查點抑製劑，如pembrolizumab，在具有特定基因突變的骨髓增生異常綜合症患者亞群中顯示出良好的前景。估計在整個預期時間範圍內，將推動骨髓增生異常綜合症（MDS）治療市場的成長。

市場動態

研發的進步推動了全球骨髓增生異常綜合症治療市場的成長

研究和開發（R&D）的進步在推動骨髓增生異常綜合症治療領域的進步和創新方面發揮了重要作用。研發工作加深了研究人員對骨髓增生異常綜合症的分子機制的理解。這包括確定促使該疾病發展和進展的特定基因突變和異常情況。

通過先進的基因組測序技術，研究人員已經能夠確定骨髓增生異常綜合症的基因特徵，從而能夠進行更精確的診斷和有針對性的治療方法。

根據2022年發表在《血液學和腫瘤學雜誌》上的文章，由於MDS的分子和遺傳特徵，該疾病的發病機制得到了更好的理解，這也加速了全新治療方法的產生。不同的血液學惡性腫瘤對靶向和免疫治療反應良好。

低甲基化藥物（HMAs）的引入是MDS管理中值得注意的進展之一，特別是高風險MDS。在歷史性的隨機AZA-001試驗中，阿扎胞苷（AZA）大大增加了中位OS，從傳統治療的15個月增加到約24個月。這些統計數位已促使採用AZA作為治療高風險MDS患者的標準。

與骨髓增生異常綜合症治療相關的副作用正在阻礙全球骨髓增生異常綜合症治療市場在預測期內的成長。

骨髓增生異常症候群的治療，如化療或免疫抑制治療，可能有明顯的副作用。這些副作用可能影響病人的生活品質，並對堅持治療方案構成挑戰。

副作用包括咳嗽或呼吸急促，胃痙攣或便秘，出現新的皮疹，皮膚變紅，瘙癢，以及持續的頭痛，身體任何部位出現新的疼痛或酸痛。

此外，骨髓增生異常症候群的治療，如化療藥物或造血幹細胞移植，可能很昂貴。高昂的治療費用可能會限制那些沒有足夠保險或經濟來源的患者的治療。

COVID-19影響分析

COVID-19大流行對骨髓增生異常綜合症治療市場產生了重大影響。根據2022年4月發表在《白血病》上的文章，COVID-19與急性白血病、高危骨髓增生異常症候群、以及造血細胞移植和嵌合抗原受體T治療後的血液病患者的顯著死亡率有關。

雖然嚴重程度和預後較差，但臨床症狀和體徵與普通人群的報告相似。截至2023年，COVID-19的情況正在恢復，患者可以進入所有的醫療機構，促使全球骨髓增生異常綜合症治療市場的需求增加。

俄羅斯與烏克蘭的衝突分析

俄烏戰爭對骨髓增生異常症候群治療市場的影響是複雜和多方面的。在地緣政治不穩定和經濟不確定的時候，疾病的負擔和醫療設施會受到影響。這可能促使治療方案的可及性不足，造成骨髓增生異常症候群的治療需求下降。

衝突可能會轉移與骨髓增生異常綜合症治療有關的研究和開發活動的資源和注意力。受影響地區的製藥公司和研究機構在進行臨床試驗、收集數據和推進新型療法方面可能面臨挑戰。

在直接受衝突影響的地區，醫護人員和病人可能會流離失所，促使骨髓增生異常綜合症治療服務中斷。患者可能難以進入醫療機構，促使診斷和治療的延誤。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按治療類型分析
  • 按終端用戶分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 患有骨髓增生異常綜合症的人口不斷增加
    • 限制因素
      • 與藥物有關的副作用
    • 機會
      • 骨髓增生異常綜合症藥物的研究和開發
    • 影響分析

第五章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第六章：COVID-19分析

  • 對COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：人工智慧分析

第九章：按治療類型

  • 幹細胞移植
  • 免疫治療
  • 化學治療
    • 低甲基化藥物
      • 阿扎胞苷(Vidaza)
      • 地西他濱(Dacogen)
  • 免疫調節藥物
    • 來那度胺（Revlimid）。
    • 其他藥物
  • 抗發炎藥
    • Luspatercept-aamt (REBLOZYL)
    • 其他
  • 其他
    • 阿糖胞苷(Cytosar-U)
    • 多柔比星(Cerubidine)
    • 伊達魯比星(伊達黴素)
    • inqovi (astx727)

第十章：按終端用戶

  • 醫院
  • 專業診所
  • 其他終端用戶

第十一章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第十二章：競爭格局

  • 競爭格局
  • 產品標杆
  • 公司佔有率分析
  • 主要發展和戰略

第十三章：公司簡介

  • AbbVie Inc.
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Pharmaceuticals
  • Otsuka America Pharmaceutical Inc.
  • Onconova Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Astex Pharmaceuticals, Inc.

第十四章：附錄

簡介目錄
Product Code: PH2678

Market Overview

The Global Myelodysplastic Syndrome (MDS) Treatment Market reached US$ 3,065.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,059.5 million by 2030. The global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

Stem cell transplantation is one of the major trends driving the global myelodysplastic syndrome treatment market. A curative therapeutic option for myelodysplastic syndrome patients, hematopoietic stem cell transplantation (HSCT), has also been the subject of R&D work. The factors influencing transplantation success, such as donor selection, conditioning regimens, and graft-versus-host disease preventive techniques, have been better understood via research.

Furthermore, the development of immunotherapies for myelodysplastic syndrome is another area of research and development. These treatments use the immune system of the body to find and destroy malignant or sick cells. For instance, immune checkpoint inhibitors, such as pembrolizumab, have shown promise in subsets of MDS patients with specific genetic mutations. estimated to fuel the growth of the Myelodysplastic Syndrome (MDS) Treatment market throughout the anticipated time frame.

Market Dynamics

Advancements in Research and Development are Boosting the Global Myelodysplastic Syndrome Treatment Market Growth

Advancements in research and development (R&D) have played a significant role in driving progress and innovation in the field of myelodysplastic syndrome treatment. R&D efforts have deepened researchers' understanding of the molecular mechanisms underlying myelodysplastic syndrome. This includes identifying specific genetic mutations and abnormalities that contribute to the development and progression of the disease.

Through advanced genomic sequencing techniques, researchers have been able to characterize the genetic landscape of MDS, allowing for more precise diagnosis and targeted treatment approaches.

As per the article published in the Journal of Hematology and Oncology in 2022, the pathogenesis of the disease has been better understood because of the molecular and genetic characterization of MDS, which has also sped up the creation of brand-new treatments. Different hematologic malignancies have responded well to targeted and immune treatments.

The introduction of hypomethylating drugs (HMAs) is one of the noteworthy advancements in the management of MDS, particularly high-risk-MDS. In the historic randomized AZA-001 trial, azacitidine (AZA) considerably increased the median OS from 15 months with conventional treatments to about 24 months. These statistics have led to the adoption of AZA as the norm for treating individuals with high risk-MDS.

Side Effects Associated with Myelodysplastic Syndrome Treatment are Hampering the Global Myelodysplastic Syndrome Treatment Market Growth in the Forecast Period.

Myelodysplastic syndrome treatments, such as chemotherapy or immunosuppressive therapy, can have significant side effects. These side effects may impact the patient's quality of life and pose challenges in adhering to the treatment regimen.

The side effects include coughing or shortness of breath, stomach cramps or constipation, a new rash, reddening of the skin, itching, and a persistent headache, new pain or soreness anywhere on the body.

In addition, myelodysplastic syndrome treatments, such as chemotherapy drugs or hematopoietic stem cell transplantation, can be expensive. The high cost of treatment may limit access for patients who do not have adequate insurance coverage or financial resources.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the myelodysplastic syndrome treatment market. According to the article published in Leukemia in April 2022, COVID-19 has been linked to a significant mortality rate in hematological patients with acute leukemia, high-risk myelodysplastic syndromes, and following hematopoietic cell transplant and chimeric antigen receptor T treatments.

Although the severity and prognosis were worse, the clinical symptoms and signs were similar to those reported for the general population. As of 2023, the COVID-19 situation is recovering and patients can access all healthcare facilities leading to an increasing demand for the myelodysplastic syndrome treatment market worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the myelodysplastic syndrome treatment market is complex and multifaceted. In times of geopolitical instability and economic uncertainty, the burden of disease and healthcare facilities can be affected. This can result in a lack of accessibility of treatment options resulting in decreased demand for treatment of the myelodysplastic syndrome.

The conflict may divert resources and attention away from research and development activities related to myelodysplastic syndrome treatments. Pharmaceutical companies and research institutions in the affected regions may face challenges in conducting clinical trials, collecting data, and advancing novel therapies.

In regions directly affected by the conflict, healthcare professionals and patients may be displaced, resulting in the disruption of myelodysplastic syndrome treatment services. Patients may have difficulty accessing healthcare facilities, leading to delays in diagnosis and treatment initiation.

Segment Analysis

The global myelodysplastic syndrome treatment market is segmented based on treatment type, end-user, and region.

The Stem Cell Transplant Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The stem cell transplant segment accounted for the highest market stake accounting for approximately 27.3% of the myelodysplastic syndrome treatment market. Patients with myelodysplastic syndromes may benefit from stem cell transplantation as a treatment.

An allogeneic stem cell transplant and an autologous stem cell transplant are the two main varieties of SCT. After the patient's bone marrow is removed during an allogeneic stem cell transplant, the donor's blood-forming stem cells are given to the patient. This kind of transplant is frequently utilized for MDS.

The patient's own stem cells, which were extracted prior to therapy, are given back during an autologous stem cell transplant. Patients with myelodysplastic syndrome are often not candidates for this sort of transplant because their bone marrow includes aberrant stem cells.

The only treatment available today that can induce long-lasting remission is high-dose chemotherapy combined with a bone marrow/stem cell transplant. However, because transplantation carries a higher risk of side effects, it may not be suggested for people who are older or have additional health issues.

An allogeneic transplant, however, might be an option for people between the ages of 50 and 75 after less intense therapy. The surgeon will discuss the risks of transplantation in detail before recommending it. They will also take into account the age and general health, the subtype of myelodysplastic syndrome, the outcomes of any prior treatments, and many other things.

Geographical Analysis

Increasing Research and Development and Advancement in Myelodysplastic Syndrome Treatment Dominate the North American Region

North America is expected to dominate the myelodysplastic syndrome treatment market, accounting for around 41.6% of this market. In December 2022, Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the start of Phase 1 clinical trial of ACLX-002 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes, as well as the continuation of robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma.

Furthermore, in December 2022, Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, presented at the 64th American Society of Haematology (ASH) Annual Meeting and Exposition encouraging Phase 1 dose escalation data from the current Phase 1/1b clinical research of PRGN-3006 UltraCAR-T in patients with r/r AML and higher risk myelodysplastic syndromes.

Competitive Landscape

The major global players in the market include: AbbVie Inc., Accord Healthcare, Bristol-Myers Squibb, Jazz Pharmaceuticals Inc., Novartis AG, Lupin Pharmaceuticals, Otsuka America Pharmaceutical Inc., Onconova Therapeutics, Takeda Pharmaceutical Company Limited, and Astex Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global myelodysplastic syndrome treatment market segmentation based on the treatment type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of myelodysplastic syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global myelodysplastic syndrome treatment market report would provide approximately 54 tables, 50 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing population with myelodysplastic syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the medications
    • 4.1.3. Opportunity
      • 4.1.3.1. Research and development of myelodysplastic syndrome drugs
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Stem Cell Transplant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Immune Treatments
  • 9.4. Chemotherapy
    • 9.4.1. Hypomethylating Agents
      • 9.4.1.1. Azacitidine (Vidaza)
      • 9.4.1.2. Decitabine (Dacogen)
  • 9.5. Immunomodulatory Drugs
    • 9.5.1. Lenalidomide (Revlimid)
    • 9.5.2. Others
  • 9.6. Anti-anemics
    • 9.6.1. Luspatercept-aamt (REBLOZYL)
    • 9.6.2. Others
  • 9.7. Others
    • 9.7.1. Cytarabine (Cytosar-U)
    • 9.7.2. Daunorubicin (Cerubidine)
    • 9.7.3. Idarubicin (Idamycin)
    • 9.7.4. INQOVI (ASTX727)

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Other End Users

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.5.1. The U.S.
      • 11.2.5.2. Canada
      • 11.2.5.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. The U.K.
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. AbbVie Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Accord Healthcare
  • 13.3. Bristol-Myers Squibb
  • 13.4. Jazz Pharmaceuticals Inc.
  • 13.5. Novartis AG
  • 13.6. Lupin Pharmaceuticals
  • 13.7. Otsuka America Pharmaceutical Inc.
  • 13.8. Onconova Therapeutics
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Astex Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us